

Lymphoma Research Foundation

Consolidated Financial Statements Year Ended June 30, 2022

Lymphoma Research Foundation

Consolidated Financial Statements
Year Ended June 30, 2022

Lymphoma Research Foundation

Contents

Independent Auditor's Report	3-4
Consolidated Financial Statements	
Consolidated Statement of Financial Position as of June 30, 2022	6
Consolidated Statement of Activities for the Year Ended June 30, 2022	7
Consolidated Statement of Functional Expenses for the Year Ended June 30, 2022	8
Consolidated Statement of Cash Flows for the Year Ended June 30, 2022	9
Notes to Consolidated Financial Statements	10-21



Tel: 212-371-4446
Fax: 212-371-9374
www.bdo.com

622 Third Ave, Suite 3100
New York, NY 10017

Independent Auditor's Report

The Board of Directors
Lymphoma Research Foundation
New York, New York

Opinion

We have audited the consolidated financial statements of Lymphoma Research Foundation, which comprise the consolidated statement of financial position as of June 30, 2022, the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying 2022 consolidated financial statements present fairly, in all material respects, the financial position of Lymphoma Research Foundation as of June 30, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (U.S. GAAS). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of Lymphoma Research Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Other Matter

The 2021 consolidated financial statements of Lymphoma Research Foundation were audited by other auditors, whose report dated December 3, 2021 expressed an unmodified opinion on those statements.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Lymphoma Research Foundation's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued or available to be issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with U.S. GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with U.S. GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Lymphoma Research Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Lymphoma Research Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

BDO USA, LLP

February 24, 2023

Consolidated Financial Statements

Lymphoma Research Foundation

Consolidated Statement of Financial Position (with comparative totals for 2021)

<i>June 30,</i>	2022	2021
Assets		
Current Assets		
Cash and cash equivalents	\$ 9,111,263	\$ 5,490,247
Investments, at fair value (Notes 2 and 4)	23,159,618	20,746,950
Contributions and grants receivable, current portion, net (Notes 2 and 3)	488,721	4,564,682
Prepaid expenses and other assets	285,347	235,074
Total Current Assets	33,044,949	31,036,953
Contributions Receivable , net of current portion and discount (Notes 2 and 5)	2,401,505	15,000
Fixed Assets, Net (Notes 2 and 6)	99,724	155,148
Total Assets	\$ 35,546,178	\$ 31,207,101
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses (Note 9)	\$ 798,559	\$ 411,617
Accrued salaries and vacation	254,305	211,384
Refundable advances (Note 2)	195,373	279,250
Research and patient aid grants payable, current (Note 7)	894,390	3,199,409
Total Current Liabilities	2,142,627	4,101,660
Research and patient aid grants payable, less current portion (Note 7)	5,847,500	-
Loan payable (Note 2)	-	486,300
Total Liabilities	7,990,127	4,587,960
Commitments (Notes 2, 3, 5, 7, 8, 9, and 10)		
Net Assets		
Without donor restrictions	5,715,532	5,562,400
With donor restrictions (Note 10)	21,840,519	21,056,741
Total Net Assets	27,556,051	26,619,141
Total Liabilities and Net Assets	\$ 35,546,178	\$ 31,207,101

See accompanying notes to consolidated financial statements.

Lymphoma Research Foundation

Consolidated Statement of Activities (with comparative totals for 2021)

Year ended December 31,

	Without Restrictions	With Donor Restrictions	Total	
			2022	2021
Revenues and Support				
Contributions and grants	\$ 2,615,589	\$ 9,527,628	\$ 12,143,217	\$ 13,758,046
Contributions of nonfinancial assets	1,144,459	-	1,144,459	1,123,970
Special events, net of expenses of \$58,000 and \$49,715 for 2022 and 2021, respectively)	1,903,845	-	1,903,845	2,136,943
Investment (loss) income, net of fees	(717,657)	-	(717,657)	60,683
Other Income	22,100	-	22,100	39,700
Net assets released from restrictions (Note 10)	8,743,850	(8,743,850)	-	-
Total Revenues and Support	13,712,186	783,778	14,495,964	17,119,342
Expenses				
Program services:				
Educational programs and patient services	2,188,429	-	2,188,429	1,761,770
Research and patient aid	7,813,502	-	7,813,502	3,776,196
Communication and advocacy	1,254,573	-	1,254,573	1,254,678
Total Program Services	11,256,504	-	11,256,504	6,792,644
Supporting services:				
Administration	788,906	-	788,906	826,691
Fundraising	1,999,944	-	1,999,944	1,593,409
Total Supporting Services	2,788,850	-	2,788,850	2,420,100
Total Expenses	14,045,354	-	14,045,354	9,212,744
Change in Net Assets, before non-operating revenue	(333,168)	783,778	450,610	7,906,598
Non-Operating Revenue				
Forgiveness of Paycheck Protection Program loan (Note 2)	486,300	-	486,300	-
Total Non-Operating Revenue	486,300	-	486,300	-
Change in Net Assets	153,132	783,778	936,910	7,906,598
Net Assets, beginning of year	5,562,400	21,056,741	26,619,141	18,712,543
Net Assets, end of year	\$ 5,715,532	\$ 21,840,519	\$ 27,556,051	\$ 26,619,141

See accompanying notes to consolidated financial statements.

Lymphoma Research Foundation

Consolidated Statement of Functional Expenses (with comparative totals for 2021)

Year ended June 30,

	Program Services				Supporting Services			Total	
	Educational Programs and Patient Services	Research and Patient Aid	Communications and Advocacy	Total Program Services	Administration	Fundraising	Total Supporting Services	2022	2021
Salaries and Related Expenses									
Salaries	\$ 784,504	\$ 423,483	\$ 309,059	\$ 1,517,046	\$ 340,785	\$ 900,074	\$ 1,240,859	\$ 2,757,905	\$ 2,350,011
Payroll, taxes, and employee benefits	184,744	99,726	72,781	357,251	243,984	211,959	455,943	813,194	676,781
Total Salaries and Related Expenses	969,248	523,209	381,840	1,874,297	584,769	1,112,033	1,696,802	3,571,099	3,026,792
Other Expenses									
Research and patient aid grants	35,500	5,531,602	-	5,567,102	-	-	-	5,567,102	2,129,925
Conferences and events	99,308	258,932	107,501	465,741	1,664	178,296	179,960	645,701	279,222
Dues and subscriptions	64,992	76,470	42,260	183,722	21,902	91,628	113,530	297,252	251,565
Insurance	8,876	4,791	3,497	17,164	3,856	10,184	14,040	31,204	30,395
Licenses and permits	2,481	1,340	978	4,799	2,885	3,612	6,497	11,296	12,417
Marketing and promotion	134,636	50,818	256,703	442,157	277	17,023	17,300	459,457	572,128
Processing fees and other	16,055	6,335	6,123	28,513	2,973	93,319	96,292	124,805	106,027
Office equipment	6,252	3,135	2,288	11,675	2,523	20,974	23,497	35,172	25,262
Office supplies	25,926	11,453	6,248	43,627	9,076	28,188	37,264	80,891	13,308
Postage and shipping	34,123	1,696	2,620	38,439	1,105	25,119	26,224	64,663	109,335
Printing and publications	111,354	15,922	7,068	134,344	1,586	21,542	23,128	157,472	119,341
Professional Fees	503,356	1,108,839	381,505	1,993,700	92,042	204,241	296,283	2,289,983	1,951,396
Rent and utilities	108,412	58,522	42,709	209,643	47,094	124,383	171,477	381,120	394,388
Repairs and maintenance	3,799	2,051	1,497	7,347	1,769	4,359	6,128	13,475	23,891
Telecommunications	34,141	5,287	3,858	43,286	5,498	11,237	16,735	60,021	66,930
Travel	11,273	143,007	512	154,792	1,765	32,355	34,120	188,912	42,694
Depreciation and amortization	18,697	10,093	7,366	36,156	8,122	21,451	29,573	65,729	57,728
Total Expenses	\$ 2,188,429	\$ 7,813,502	\$ 1,254,573	\$ 11,256,504	\$ 788,906	\$ 1,999,944	\$ 2,788,850	\$ 14,045,354	\$ 9,212,744

See accompanying notes to consolidated financial statements.

Lymphoma Research Foundation

Consolidated Statement of Cash Flows (with comparative totals for 2021)

<i>Year ended June 30,</i>	2022	2021
Cash Flows from Operating Activities		
Change in net assets	\$ 936,910	\$ 7,906,598
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	65,729	57,728
Realized (gain) loss on sale of investments	(945)	2,692
Unrealized loss on investments	872,122	170,804
Change in discount on contributions receivable	98,495	-
Forgiveness of Paycheck Protection Program loan	(486,300)	-
(Increase) decrease in:		
Contributions receivable	1,590,961	(3,506,012)
Prepaid expenses and other assets	(50,273)	(12,746)
Increase (decrease) in:		
Accounts payable and accrued expenses	386,942	20,265
Accrued payroll, vacation, and related taxes payable	42,921	2,234
Refundable advances	(83,877)	(16,750)
Research and patient aid grants payable	3,542,481	585,111
Net Cash Provided by Operating Activities	6,915,166	5,209,924
Cash Flows from Investing Activities		
Proceeds from sale of investments	5,234,543	6,858,778
Purchase of investments	(8,518,388)	(9,724,247)
Purchase of fixed assets	(10,305)	(20,730)
Net Cash Used in Investing Activities	(3,294,150)	(2,886,199)
Net Increase in Cash and Cash Equivalents	3,621,016	2,323,725
Cash and Cash Equivalents, beginning of year	5,490,247	3,166,522
Cash and Cash Equivalents, end of year	\$ 9,111,263	\$ 5,490,247

See accompanying notes to consolidated financial statements.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

1. Nature of Organization

The Lymphoma Research Foundation (the Foundation) is a nonprofit corporation, which is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and similar provisions at the state and local level. The Foundation is the nation's largest nonprofit organization devoted to only funding innovative lymphoma research and providing patients and their families and healthcare professionals with up-to-date education about this type of cancer. The Foundation's mission is to eradicate lymphoma and serve those touched by this disease. The Foundation's primary sources of income are contributions and grants.

To help ensure that the amounts the Foundation raises are directed toward cutting-edge lymphoma-related research, decisions of what research will be funded are made by the deliberations of the Foundation's Scientific Advisory Board (SAB). The SAB comprises a volunteer group of scientists and clinicians distinguished in the fields of lymphoma research and treatment. They make their judgments on applications for funding based on the scientific and innovative merits of the projects proposed, the demonstrated ability of the researcher and sponsor, and the suitability of the institution. The members of the SAB review the applications independently and then meet to discuss the proposals at periodic meetings scheduled throughout the year.

In addition to evaluating grant applications, the SAB counsels the Foundation's board of directors and staff on the direction of its overall strategic scientific agenda in order to remain current with the pace and direction of the rapidly evolving area of blood cancer research.

The board of directors studies the recommendations of the SAB. Its aim is to approve those recommended grant applications and projects which seem most likely to have an impact on lymphoma-related research and treatments, and therefore, most likely to help the Foundation achieve its overall goals. The Foundation funds research projects submitted by individuals associated with accredited academic institutions, Joint Commission on Accreditation of Healthcare Organizations, accredited research hospitals, and other research organizations that have strong national and international reputations.

The Foundation is also dedicated to serving those touched by lymphoma. To accomplish this, the Foundation provides national, regional, and local educational conferences and symposiums; advocacy programs; online webcast educational programming; telephone educational workshops; and educational publications. The Foundation's educational programs and publications provide lymphoma patients and their loved ones with current and comprehensive information about the disease, its treatments, promising research in lymphoma, and how to better manage the psycho/social issues associated with living with lymphoma. The Foundation also offers a Lymphoma Helpline and Clinical Trials Information Service, a nationwide peer support program, and financial assistance to lymphoma patients receiving treatment.

During fiscal year 2017, the Foundation established a subsidiary, LRF Research Inc., as part of a strategic relationship with the Clarus Cancer Fund, an investment fund of Clarus Ventures. There was no activity at LRF Research Inc. for the year ended June 30, 2022.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

2. Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of LRF Research, Inc. All intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation

The Foundation's consolidated financial statements have been prepared on the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America (U.S. GAAP). In the consolidated statement of financial position, assets and liabilities are presented in order of liquidity or conversion to cash and their maturity resulting in the use of cash, respectively.

Consolidated Financial Statement Presentation

The classification of the Foundation's net assets and its support, revenue, and expenses is based on the existence or absence of donor-imposed restrictions. It requires that the amounts for each of the two classes of net assets—net assets without donor restrictions and net assets with donor restrictions—be displayed in the consolidated statement of financial position and that the amounts of change in each of those classes of net assets be displayed in the consolidated statement of activities.

These classes are defined as follows:

Net Assets Without Donor Restrictions - This class consists of the part of net assets that are not subject to donor-imposed stipulations and are, therefore, available for the general operations of the Foundation.

Net Assets with Donor Restrictions - This class consists of net assets resulting from contributions and other inflows of assets whose use by the Foundation is limited by donor-imposed stipulations that either expire by the passage of time or can be fulfilled and removed by the actions of the Foundation, pursuant to those stipulations. When such stipulations end or are fulfilled, such net assets are reclassified to net assets without donor restrictions and reported as net assets released from restrictions in the consolidated statements of activities.

Net assets with donor restrictions also include net assets resulting from contributions whereby the principal has been stipulated by the donor to be held and invested in perpetuity and the income used in accordance with the donor's stipulations, if any. At June 30, 2022, the Foundation had no net assets with donor restrictions that are perpetual in nature.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with an original maturity of 90 days or less when acquired to be cash equivalents, except for those cash equivalents held for short-term investment that are maintained in the Foundation's investment portfolio.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

The Foundation maintains its cash in bank deposit accounts, which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Foundation does not believe it is exposed to any significant risk from cash and cash equivalents.

Fair Value Measurements

The Foundation follows Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, which establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Foundation. Unobservable inputs are inputs that reflect the Foundation's assumptions about the factors market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs, as follows:

Level 1 - Valuations are based on quoted prices in active markets for identical assets or liabilities. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 - Valuations are based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 2 inputs include: (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical assets or liabilities traded in non-active markets (i.e., dealer or broker markets), and (iii) inputs other than quoted prices that are observable, or inputs derived from or corroborated by market data.

Level 3 - Valuations are based on inputs that are unobservable and significant to the overall fair value measurement.

Investment Income

Investment income is recognized when earned and consists of interest, dividends, and realized and unrealized gains and losses, less direct external investment expenses. Dividends are recorded at the ex-dividend date. Purchases and sales are recorded on a trade-date basis.

Income earned from investments restricted in perpetuity, including realized and unrealized gains and losses, are recorded as net assets with donor restrictions and then released to net assets without donor restrictions through appropriations made in accordance with the Foundation's spending policy.

Contributions

Contributions received, including unconditional promises to give are reported at their net realizable values. Gifts of cash and other assets are reported as support with donor restrictions if they are received with donor stipulations that limit their use or if they are intended to support activities in future periods. Contributions with donor-imposed restrictions that limit their use are reported in net assets with donor restrictions until the donor restrictions expire—that is, when a time restriction ends or purpose restriction is fulfilled. Upon the expiration of donor stipulations, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the accompanying consolidated statements of activities as net assets released from restrictions.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

Contributions are nonexchange transactions in which no commensurate value is exchanged. Therefore, contributions fall under the purview of ASC Topic 958, *Not-for-Profit Entities*.

A contribution, gift, or grant is conditional if an agreement includes a barrier that must be overcome and either a right of return of assets transferred or a right of release of a promisor's obligation to transfer assets. The presence of both a barrier and a right of return or right of release indicates that a recipient's promises to give are not recognized until they become unconditional—that is, when the barriers in the agreement are overcome. There are no outstanding conditional grants as of June 30, 2022.

Management determines the allowance for doubtful contributions receivable by regularly evaluating individual contributions receivable and considering prior history of donors and proven collectability of past donations. Contributions receivable are written off when deemed uncollectible.

Contributed Nonfinancial Assets

Amounts are reported in the consolidated financial statements for voluntary donations of services if those services create or enhance non-financial assets or require specialized skills provided by individuals possessing those skills and which would typically be purchased if not provided by donation. During the year ended June 30, 2022, the Foundation received \$1,144,459, in contributions in kind that are reported as contributions and expenses in the accompanying consolidated statements of activities and functional expenses. The amount includes \$129,496 and \$1,014,963, recognized in revenue and expenses from Google grants, and associated with the recognition of time spent by SAB members to carry out the requirements of its research program, as well as support the Foundation's professional and patient education programs, respectively. Without the volunteer support these physicians provide the Foundation, the organization would be required to compensate physicians to perform these services.

A substantial number of other volunteers have donated significant amounts of their time in supporting the Foundation's activities. No amounts have been reflected in the accompanying consolidated financial statements for these donated services since they do not meet the criteria for recognition.

The following summarizes the Foundation's contributed nonfinancial assets for the year ended June 30, 2022:

	Revenue Recognized	Donor Restrictions	Valuation Techniques and Inputs
Professional services	\$ 1,144,459	No associated donor restrictions	Valued based on prevailing rates of professional time

Small Business Administration - Paycheck Protection Program Loan Forgiveness

The Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) was enacted by the President of the United States on March 27, 2020, which appropriated funds for the United States Small Business Administration (SBA) Paycheck Protection Program (PPP) loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by the COVID-19 outbreak.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

In April 2020, the Foundation applied and received approval for a loan in the amount of \$486,300 under the PPP administered by the United States SBA. The loan was recorded as a loan payable in fiscal year 2021. The PPP loan had an interest at a rate of 1%, with an original maturity date of two years from the date of the loan.

The PPP loans may be fully or partially forgiven if the Foundation meets the PPP criteria for the forgiveness of the loan. On July 15, 2021, the SBA has authorized full forgiveness of the PPP loan in the amount of \$486,300. The Foundation recognized the loan forgiveness as income in fiscal year 2022 following the guidance of ASC 405-20, *Extinguishment of Liabilities*. This is presented as nonoperating revenue in the consolidated statement of activities.

Fixed Assets

Fixed assets are stated at cost or at their fair market values at the time of their donation. The Foundation capitalizes additions that are purchased if the estimated useful life is greater than one year. Depreciation is computed over the estimated useful lives of the assets by the straight-line method for financial reporting, as follows:

Furniture and office equipment	2-5 years
Computer equipment and software	2 years
Leasehold improvements	Lesser of lease term or useful life

Impairment of Long-Lived Assets

The Foundation follows the provisions of ASC 360-10-35, *Accounting for the Impairment or Disposal of Long-Lived Assets*, which requires the Foundation to review long-lived assets, including both fixed and intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future cash flows from the use of the asset are less than the carrying amount of that asset. For the year ended June 30, 2022, there were no impairments recorded in the consolidated financial statements.

Grant Expense

Grant expense is recognized in the period the grant is approved by the Foundation's Board of Directors, provided the grant is not subject to significant future conditions.

Refundable Advances

Amounts received by the Foundation for certain special events are reflected as refundable advances until the event occurs. The majority of these amounts are characterized by the Foundation as an exchange transaction.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis. The consolidated statements of functional expenses present expenses by function and natural classification. Where practicable, expenses are directly classified to specific program

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

or supporting service categories. Costs that are not specifically identifiable within functional categories are classified using an allocation methodology based on an estimate of time and effort.

Income Taxes

The Foundation follows U.S. GAAP, which requires accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and measurement. U.S. GAAP provides that the tax effects from an uncertain tax position can only be recognized in the consolidated financial statements if the position is “more likely than not” to be sustained if the position were to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged.

The Foundation is incorporated in the state of New York and is exempt from federal income tax under IRC section 501(c)(3), though it is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the IRC. The Organization has no unrelated income associated with its exempt purpose. The Foundation has processes presently in place to ensure the maintenance of its tax-exempt status, to identify and report unrelated income, to determine its filing and tax obligations in jurisdictions for which nexus was established, and to identify and evaluate other matters that may be considered tax positions. The Foundation has determined that there are no material uncertain tax positions that require recognition or disclosure in the consolidated financial statements. As of December 31, 2021, the Foundation was not subject to an examination by a taxing authority.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the consolidated financial statements and revenue and expenses recognized during the reporting period. Estimates made in the preparation of the consolidated financial statements include the net realizable value of contributions and grants receivable, the valuation of contributed services, and functional expense allocations. Actual results could differ from those estimates.

Reclassifications

Certain prior-year balances have been reclassified to be consistent with the current-year consolidated financial statements’ presentation. These reclassifications had no impact on change in net assets or ending net assets.

Comparative Financial Information

The consolidated financial statements include certain prior year summarized comparative information. With respect to the consolidated statement of activities, the prior-year information is presented in total, not by net asset class. With respect to the consolidated statement of functional expenses, the prior-year expenses are presented by expense classification in total rather than functional category. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Foundation’s consolidated financial statements for the year ended June 30, 2021, from which the summarized information was derived.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

Accounting Pronouncement Recently Adopted

Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets

In September 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This ASU is intended to increase transparency on how contributed nonfinancial assets (also referred to as gifts-in-kind) received by nonprofits are to be used and how they are valued. The provisions of ASU 2020-07 were adopted by the Foundation beginning July 1, 2021. Effective July 1, 2021, the Foundation elected the retrospective approach in adopting ASU 2020-07 to all contributed nonfinancial assets under the scope of the guidance. The adoption of this ASU did not have a material impact on the consolidated financial statements.

Recently Issued but Not Yet Adopted Accounting Pronouncements

Accounting for Leases

In February 2016, the FASB issued ASU 2016-02, *Accounting for Leases*, which applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating based on five criteria. Balance sheet recognition of finance and operating leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement of cash flows, differs depending on the lease classification. In addition, lessees and lessors are required to provide certain qualitative and quantitative disclosures to enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The FASB issued ASU 2020-05, which deferred the effective date for the Foundation until annual periods beginning after December 15, 2021. Management is currently evaluating the impact of this ASU on its consolidated financial statements.

Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, which creates a new credit impairment standard for financial assets measured at amortized cost and available-for-sale debt securities. The ASU requires financial assets measured at amortized cost (including loans, trade receivables, and held-to-maturity debt securities) to be presented at the net amount expected to be collected, through an allowance for credit losses that are expected to occur over the remaining life of the asset, rather than incurred losses. The ASU requires that credit losses on available-for-sale debt securities be presented as an allowance rather than as a direct write-down. The measurement of credit losses for newly recognized financial assets (other than certain purchased assets) and subsequent changes in the allowance for credit losses are recorded in the statement of income as the amounts expected to be collected change. The ASU is effective for fiscal years beginning after December 15, 2022. Management is currently evaluating the impact of adopting this new guidance on its consolidated financial statements.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

3. Contributions and Grants Receivable

Contributions and grants receivable are scheduled to be collected as follows:

<i>June 30,</i>		2022		2021
Amount due in one year or less	\$	488,721	\$	4,564,682
Amount due in one to five years		2,500,000		15,000
Less: discount on contributions receivable		(98,495)		-
Contributions and Grants Receivable, Net	\$	2,890,226	\$	4,579,682

4. Investments, at Fair Value

The Foundation's assets recorded at fair value have been categorized based upon a fair value hierarchy, in accordance with ASC 820. See Note 2 for a discussion of the Foundation's policies regarding this hierarchy.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used as of June 30, 2022.

Money Market Funds - The Foundation has investments in money market funds. The Foundation's custodian prices these investments using nationally recognized pricing services. These investments are classified as Level 1.

Certificates of Deposit - The Foundation has certificates of deposit (CDs) having original maturities greater than 90 days. The CDs are maintained at a number of financial institutions. As of June 30, 2022, there was no exposure of credit risk that exceeded the Federal Deposit Insurance Corporation insurance limits for the CDs. These investments are classified as Level 2.

The following tables present the level within the fair value hierarchy at which the Foundation's assets are measured on a recurring basis:

June 30, 2022

		Total		Level 1		Level 2
Investments						
Money market fund	\$	4,468,517	\$	4,468,517	\$	-
Certificates of deposit		18,691,101		-		18,691,101
Total Investments, at fair value	\$	23,159,618	\$	4,468,517	\$	18,691,101

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

June 30, 2021

	Total	Level 1	Level 2
Investments			
Money market fund	\$ 604	\$ 604	\$ -
Certificates of deposit	20,746,346	-	20,746,346
Total Investments, at fair value	\$ 20,746,950	\$ 604	\$ 20,746,346

Investment (loss) income consists of the following:

<i>Years ended June 30,</i>	2022	2021
Interest and dividends	\$ 153,520	\$ 234,179
Realized and unrealized loss on investments	(871,177)	(173,496)
	\$ (717,657)	\$ 60,683

5. Liquidity and Availability of Resources

The Foundation's financial assets available within one year of the consolidated balance sheet date for general expenditures, such as program expenses, grants, and other operating expenses, are as follows:

<i>June 30,</i>	2022	2021
Net Financial Assets		
Cash and cash equivalents	\$ 9,111,263	\$ 5,490,247
Contributions and grants receivable	2,890,226	4,579,682
Investments	23,159,618	20,746,950
Total Financial Assets, end of year	35,161,107	30,816,879
Less: those unavailable for general expenditure within one year, due to:		
Contributions receivable due in greater than one year	-	(15,000)
Donor-imposed program restrictions	(21,840,519)	(21,056,741)
Total Financial Assets Available Within One Year	\$ 13,320,588	\$ 9,745,138

The Foundation's board of directors approves an annual operating budget and cash availability sufficient to meet projected cash needs. The Foundation maintains cash and highly liquid securities sufficient to meet anticipated cash needs for operations, capital commitments, and new investments over a 12-month rolling period.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

6. Fixed Assets, Net

Major classes of fixed assets, net, consist of the following:

<i>June 30,</i>	2022	2021
Furniture and office equipment	\$ 200,427	\$ 198,748
Computer equipment and software	68,198	59,574
Leasehold improvements	113,640	113,640
Property and Equipment	382,265	371,962
Less: accumulated depreciation and amortization	(282,541)	(216,814)
Property and Equipment, Net	\$ 99,724	\$ 155,148

Depreciation expense amounted to \$65,729 for the year ended June 30, 2022.

7. Research and Patient Aid Grants

Research grant expense is recorded when the grant is approved by the Foundation and the grantee is notified and has executed the award. Research grants are generally awarded for a two to three-year period, with payments made quarterly.

The Foundation offers a financial assistance program for people currently undergoing treatment for lymphoma. Patient aid grants assist with quality-of-life expenses.

The following table provides grant activity for fiscal years 2022 and 2021:

<i>Years ended June 30,</i>	2022	2021
Research and Patient Aid Grants Payable,		
beginning of year	\$ 3,199,409	\$ 2,614,298
Grants awarded, net of cancellations	5,555,000	2,136,651
Grant payments	(2,012,519)	(1,551,540)
Research and Patient Aid Grants Payable, end of year	\$ 6,741,890	\$ 3,199,409

Research and patient aid grants payable are scheduled to be paid as follows:

<i>June 30,</i>	2022	2021
Amount payable in one year or less	\$ 894,390	\$ 1,411,409
Amount payable in more than one year	5,847,500	1,788,000
	\$ 6,741,890	\$ 3,199,409

In 2022, the Foundation authorized research grant awards of \$5,715,000, which included the re-awarded 2021 amount, for which grant agreements were provided to recipients. Of this amount, approximately \$5,012,500 of the grant agreements were not executed by the prospective grantee or the grantee did not utilize all of the funds. The grant awards not executed will be awarded in fiscal year 2023 to other grantees.

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

8. Employee Benefit Plan

The Foundation maintains a retirement plan pursuant to Internal Revenue Code Section 403(b) for its employees. Employees are eligible to participate immediately. Under the terms of the plan, employees are entitled to defer a portion of their annual compensation, within limitations established by the Internal Revenue Code. During 2006, the Foundation started a matching program whereby it contributes an amount equal to 5% of annual compensation for eligible employees provided that the employees contribute at least 3% to the plan. Retirement expense under the plan amounted to approximately \$95,000 and \$85,000 for the years ended June 30, 2022 and 2021, respectively.

9. Commitments

The Foundation entered into a ten-year lease agreement at 88 Pine Street, New York, NY 10005, effective March 17, 2017. Minimum annual rentals related to this lease are approximately as follows for the years ended subsequent to June 30, 2022:

Year ended June 30,

2023	\$	404,000
2024		404,000
2025		404,000
2026		404,000
2027		404,000
Thereafter		67,000
	\$	2,087,000

The Foundation leases its New York City office, whereby the landlord has provided periods of free rent. The Foundation recorded a liability for this free rent that it amortizes on a straight-line basis over the life of the lease. Included in accounts payable and accrued expenses is deferred rent of \$93,019 and \$110,879 as of June 30, 2022 and 2021, respectively.

Rent and utilities expense for the years ended June 30, 2022 and 2021 amounted to approximately \$381,000 and \$394,000, respectively.

10. Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following:

<i>June 30,</i>	2022	2021
Research program	\$ 7,228,006	\$ 8,924,440
Patient and professional programs	14,375,712	11,938,806
Patient aid	236,801	193,495
	\$ 21,840,519	\$ 21,056,741

Lymphoma Research Foundation

Notes to Consolidated Financial Statements

Net assets were released from restrictions during the years ended June 30, 2022 and 2021 by incurring expenses or the passage of time, thus satisfying the restricted purposes as follows:

<i>Years ended June 30,</i>	2022	2021
Research program	\$ 6,627,106	\$ 2,499,635
Patient and professional programs	2,081,244	1,727,598
Patient aid	35,500	37,600
	\$ 8,743,850	\$ 4,264,833

11. Subsequent Events

In connection with the preparation of the consolidated financial statements, the Foundation evaluated subsequent events after the consolidated balance sheet date of June 30, 2022 through February 24, 2023, which was the date the consolidated financial statements were available to be issued, and determined that there were no additional matters that are required to be disclosed besides what noted below.